All In Biotech

Free tool

FAERS Monitor: Valstar Preservative Free

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020892 or its brand name (Valstar Preservative Free, Valrubicin). Reports on generic versions are filed under their own applications.

Reports

178

Serious

30

17% of reports

Hospitalization

8

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • underdose26
  • bladder instillation procedure24
  • accidental exposure to product23
  • urge incontinence20
  • bladder spasm13
  • urinary incontinence11
  • pain9
  • dysuria8
  • burning sensation7
  • drug ineffective7
  • arthralgia6
  • fatigue6
  • pollakiuria6
  • rash6
  • drug intolerance5

Reports by year received

View as table
YearReports
20091
20121
201379
201426
201515
20165
201710
201818
20193
20204
20215
20222
20233
20242
20253
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,981 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bladder instillation procedureSignal241419369.5337966.72,512,328
urge incontinenceSignal202783.11831.651,661
bladder spasmSignal13826.2488.69,838
urinary incontinenceSignal1143.924.8420
underdoseSignal2642.129.51,006
accidental exposure to productSignal2326.418.0539
dysuriaSignal825.713.0166
pollakiuriaSignal617.07.775
burning sensationSignal711.85.759
drug intoleranceSignal56.12.617
pain91.70.92
arthralgia61.70.81
rash61.60.71
fatigue60.90.40
drug ineffective70.60.31

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.